f Cells with Defective Mitophagy Do Not Accumulate Atherogenic LDL-Derived Cholesterol

References

1. WilkinsH.M. CarlS.M. SwerdlowR.H. Cytoplasmic hybrid (cybrid) cell lines as a practical model for mitochondriopathies.Redox Biol.2014261963110.1016/j.redox.2014.03.006 25460729
   [Google Scholar]
2. SazonovaM.A. SinyovV.V. RyzhkovaA.I. SazonovaM.D. KhasanovaZ.B. ShkuratT.P. KaragodinV.P. OrekhovA.N. SobeninI.A. Creation of cybrid cultures containing mtdna mutations m.12315G>A and m.1555G>A, associated with atherosclerosis.Biomolecules20199949910.3390/biom9090499 31540444
   [Google Scholar]
3. de VriesR.L.A. GilkersonR.W. PrzedborskiS. SchonE.A. Mitophagy in cells with mtDNA mutations.Autophagy20128469970010.4161/auto.19470
   [Google Scholar]
4. YuE.P.K. BennettM.R. Mitochondrial DNA damage and atherosclerosis.Trends Endocrinol. Metab.201425948148710.1016/j.tem.2014.06.008 25034130
   [Google Scholar]
5. SalnikovaD. OrekhovaV. GrechkoA. StarodubovaA. BezsonovE. PopkovaT. OrekhovA. Mitochondrial dysfunction in vascular wall cells and its role in atherosclerosis.Int. J. Mol. Sci.20212216899010.3390/ijms22168990 34445694
   [Google Scholar]
6. OrekhovA.N. GerasimovaE.V. SukhorukovV.N. PoznyakA.V. NikiforovN.G. Do mitochondrial DNA mutations play a key role in the chronification of sterile inflammation? special focus on atherosclerosis.Curr. Pharm. Des.202127227629210.2174/1381612826666201012164330 33045961
   [Google Scholar]
7. OrekhovA.N. SummerhillV.I. KhotinaV.A. PopovM.A. UzokovJ.K. SukhorukovV.N. Role of mitochondria in the chronification of inflammation: Focus on dysfunctional mitophagy and mitochondrial DNA mutations.Gene Expr.202322432934410.14218/GE.2023.00061
   [Google Scholar]
8. HaferkampO. ScheuerleA. SchlenkR. MelznerI. Pavenstädt-GruppI. RödelG. Mitochondrial complex I and III mutations and neutral-lipid storage in activated mononuclear macrophages and neutrophils: A case presenting with necrotizing myopathy, poikiloderma atrophicans vasculare, and xanthogranulomatous bursitis.Hum. Pathol.199425441942310.1016/0046‑8177(94)90153‑8 8163275
   [Google Scholar]
9. DahmaniY. MarcuelloA. Díez-SanchezC. Ruiz-PesiniE. MontoyaJ. López-PérezM.J. Association of human mitochondrial DNA variants with plasma LDL levels.Mitochondrion20088324725310.1016/j.mito.2008.04.002 18538642
   [Google Scholar]
10. BorisovE. BezsonovE. LyukmanovD. PoggioP. MoschettaD. ValerioV. Pharmacological agents affecting mitophagy and inflammation.Vessel Plus202266310.20517/2574‑1209.2022.20
    [Google Scholar]
11. LeeK.M. YunJ. Mitophagy stimulation as a novel strategy for the treatment of mitochondrial diseases.J. Genet. Med.2022192495610.5734/JGM.2022.19.2.49
    [Google Scholar]
12. WoollardK.J. GeissmannF. Monocytes in atherosclerosis: Subsets and functions.Nat. Rev. Cardiol.201072778610.1038/nrcardio.2009.228 20065951
    [Google Scholar]
13. TabasI. LichtmanA.H. Monocyte-macrophages and T cells in atherosclerosis.Immunity201747462163410.1016/j.immuni.2017.09.008 29045897
    [Google Scholar]
14. FlynnM.C. PernesG. LeeM.K.S. NagareddyP.R. MurphyA.J. Monocytes, macrophages, and metabolic disease in atherosclerosis.Front. Pharmacol.20191066610.3389/fphar.2019.00666 31249530
    [Google Scholar]
15. FerenceB.A. MahajanN. The role of early LDL lowering to prevent the onset of atherosclerotic disease.Curr. Atheroscler. Rep.201315431210.1007/s11883‑013‑0312‑1 23423521
    [Google Scholar]
16. OrekhovA. BobryshevY. SobeninI. MelnichenkoA. ChistiakovD. Modified low density lipoprotein and lipoprotein-containing circulating immune complexes as diagnostic and prognostic biomarkers of atherosclerosis and type 1 diabetes macrovascular disease.Int. J. Mol. Sci.2014157128071284110.3390/ijms150712807 25050779
    [Google Scholar]
17. BorénJ. ChapmanM.J. KraussR.M. PackardC.J. BentzonJ.F. BinderC.J. DaemenM.J. DemerL.L. HegeleR.A. NichollsS.J. NordestgaardB.G. WattsG.F. BruckertE. FazioS. FerenceB.A. GrahamI. HortonJ.D. LandmesserU. LaufsU. MasanaL. PasterkampG. RaalF.J. RayK.K. SchunkertH. TaskinenM.R. van de SluisB. WiklundO. TokgozogluL. CatapanoA.L. GinsbergH.N. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: A consensus statement from the European Atherosclerosis Society Consensus Panel.Eur. Heart J.202041242313233010.1093/eurheartj/ehz962 32052833
    [Google Scholar]
18. JiangH. ZhouY. NabaviS.M. SahebkarA. LittleP.J. XuS. WengJ. GeJ. Mechanisms of oxidized LDL-mediated endothelial dysfunction and its consequences for the development of atherosclerosis.Front. Cardiovasc. Med.2022992592310.3389/fcvm.2022.925923 35722128
    [Google Scholar]
19. PentikäinenM.O. ÖörniK. Ala-KorpelaM. KovanenP.T. Modified LDL – trigger of atherosclerosis and inflammation in the arterial intima.J. Intern. Med.2000247335937010.1046/j.1365‑2796.2000.00655.x 10762453
    [Google Scholar]
20. OrekhovA.N. OishiY. NikiforovN.G. ZhelankinA.V. DubrovskyL. SobeninI.A. KelA. StelmashenkoD. MakeevV.J. FoxxK. JinX. KruthH.S. BukrinskyM. Modified LDL particles activate inflammatory pathways in monocyte-derived macrophages: Transcriptome analysis.Curr. Pharm. Des.201824263143315110.2174/1381612824666180911120039 30205792
    [Google Scholar]
21. JukemaR.A. AhmedT.A.N. TardifJ.C. Does low-density lipoprotein cholesterol induce inflammation? If so, does it matter? Current insights and future perspectives for novel therapies.BMC Med.201917119710.1186/s12916‑019‑1433‑3 31672136
    [Google Scholar]
22. GalleJ. Hansen-HaggeT. WannerC. SeiboldS. Impact of oxidized low density lipoprotein on vascular cells.Atherosclerosis2006185221922610.1016/j.atherosclerosis.2005.10.005 16288760
    [Google Scholar]
23. LeivaE. WehingerS. GuzmánL. OrregoR. Role of oxidized LDL in atherosclerosis.Hypercholesterolemia20153557810.5772/59375
    [Google Scholar]
24. PoznyakA.V. NikiforovN.G. MarkinA.M. KashirskikhD.A. MyasoedovaV.A. GerasimovaE.V. OrekhovA.N. Overview of OxLDL and its impact on cardiovascular health: Focus on atherosclerosis.Front. Pharmacol.20211161378010.3389/fphar.2020.613780 33510639
    [Google Scholar]
25. ZhangY.X. OuM.Y. YangZ.H. SunY. LiQ.F. ZhouS.B. Adipose tissue aging is regulated by an altered immune system.Front. Immunol.202314112539510.3389/fimmu.2023.1125395 36875140
    [Google Scholar]
26. JungJ. HuhY. ShefaU. JeongN.Y. SongI.O. ChungH-J. KimD. Mitophagy links oxidative stress conditions and neurodegenerative diseases.Neural Regen. Res.201914574975610.4103/1673‑5374.249218 30688256
    [Google Scholar]
27. WangD. JinM. ZhaoD. NiH. Reduction of mitophagy-related oxidative stress and preservation of mitochondria function using melatonin therapy in an HT22 hippocampal neuronal cell model of glutamate-induced excitotoxicity.Front. Endocrinol. (Lausanne)20191055010.3389/fendo.2019.00550 31440210
    [Google Scholar]
28. ZhangN.P. LiuX.J. XieL. ShenX.Z. WuJ. Impaired mitophagy triggers NLRP3 inflammasome activation during the progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis.Lab. Invest.201999674976310.1038/s41374‑018‑0177‑6 30700851
    [Google Scholar]
29. GuptaS. CasselS.L. SutterwalaF.S. DagvadorjJ. Regulation of the NLRP3 inflammasome by autophagy and mitophagy.Immunol. Rev.202417imr.1341010.1111/imr.1341039417249
    [Google Scholar]
30. GkikasI. PalikarasK. TavernarakisN. The role of mitophagy in innate immunity.Front. Immunol.20189128310.3389/fimmu.2018.01283 29951054
    [Google Scholar]
31. Roca-AgujetasV. Barbero-CampsE. de DiosC. PodlesniyP. AbadinX. MoralesA. MaríM. TrullàsR. ColellA. Cholesterol alters mitophagy by impairing optineurin recruitment and lysosomal clearance in Alzheimer’s disease.Mol. Neurodegener.20211611510.1186/s13024‑021‑00435‑6 33685483
    [Google Scholar]
32. Roca-AgujetasV. de DiosC. AbadinX. ColellA. Upregulation of brain cholesterol levels inhibits mitophagy in Alzheimer disease.Autophagy20211761555155710.1080/15548627.2021.1920814 33945386
    [Google Scholar]
33. SazonovaM.A. SinyovV.V. BarinovaV.A. RyzhkovaA.I. BobryshevY.V. OrekhovA.N. SobeninI.A. Association of mitochondrial mutations with the age of patients having atherosclerotic lesions.Exp. Mol. Pathol.201599371771910.1016/j.yexmp.2015.11.019 26586456
    [Google Scholar]
34. ShemiakovaT. IvanovaE. WuW.K. KirichenkoT.V. StarodubovaA.V. OrekhovA.N. Atherosclerosis as mitochondriopathy: Repositioning the disease to help finding new therapies.Front. Cardiovasc. Med.2021866047310.3389/fcvm.2021.660473 34017868
    [Google Scholar]
35. OrekhovA.N. NikiforovN.G. OmelchenkoA.V. SinyovV.V. SobeninI.A. VinokurovA.Y. OrekhovaV.A. The role of mitochondrial mutations in chronification of inflammation: Hypothesis and overview of own data.Life (Basel)2022128115310.3390/life12081153 36013333
    [Google Scholar]
36. NissankaN. MoraesC.T. Mitochondrial DNA damage and reactive oxygen species in neurodegenerative disease.FEBS Lett.2018592572874210.1002/1873‑3468.12956 29281123
    [Google Scholar]
37. GoncharovN. AvdoninP. NadeevA. ZharkikhI. JenkinsR. Reactive oxygen species in pathogenesis of atherosclerosis.Curr. Pharm. Des.20152191134114610.2174/1381612820666141014142557 25312724
    [Google Scholar]
38. GoldsteinJ.L. AndersonR.G. BrownM.S. Receptor-mediated endocytosis and the cellular uptake of low density lipoprotein.Ciba Found. Symp.19829292779510.1002/9780470720745.ch5 6129958
    [Google Scholar]
39. GhoshS. Cholesteryl ester hydrolase in human monocyte/macrophage: Cloning, sequencing, and expression of full-length cDNA.Physiol. Genomics2000211810.1152/physiolgenomics.2000.2.1.1 11015575
    [Google Scholar]
40. OkazakiH. IgarashiM. NishiM. SekiyaM. TajimaM. TakaseS. TakanashiM. OhtaK. TamuraY. OkazakiS. YahagiN. OhashiK. Amemiya-KudoM. NakagawaY. NagaiR. KadowakiT. OsugaJ. IshibashiS. Identification of neutral cholesterol ester hydrolase, a key enzyme removing cholesterol from macrophages.J. Biol. Chem.200828348333573336410.1074/jbc.M802686200 18782767
    [Google Scholar]
41. EastD.A. FagianiF. CrosbyJ. GeorgakopoulosN.D. BertrandH. SchaapM. FowkesA. WellsG. CampanellaM. PMI: A ΔΨm independent pharmacological regulator of mitophagy.Chem. Biol.201421111585159610.1016/j.chembiol.2014.09.019 25455860
    [Google Scholar]
42. LiuB.H. XuC.Z. LiuY. LuZ.L. FuT.L. LiG.R. DengY. LuoG.Q. DingS. LiN. GengQ. Mitochondrial quality control in human health and disease.Mil. Med. Res.20241113210.1186/s40779‑024‑00536‑5 38812059
    [Google Scholar]
43. BenzR. McLaughlinS. The molecular mechanism of action of the proton ionophore FCCP (carbonylcyanide p-trifluoromethoxyphenylhydrazone).Biophys. J.198341338139810.1016/S0006‑3495(83)84449‑X 6838976
    [Google Scholar]
44. SamartsevV.N. BelosludtsevK.N. PavlovaE.K. PavlovaS.I. SemenovaA.A. DubininM.V. Theoretical and experimental study of the interaction of protonophore uncouplers and decoupling agents with functionally active mitochondria.Cell Biochem. Biophys.20248232333234510.1007/s12013‑024‑01343‑4 38856833
    [Google Scholar]
45. XieY. LiJ. KangR. TangD. Interplay between lipid metabolism and autophagy.Front. Cell Dev. Biol.2020843110.3389/fcell.2020.00431 32582708
    [Google Scholar]
46. SobeninI.A. TertovV.V. KoschinskyT. BüntingC.E. SlavinaE.S. DedovcI.I. OrekhovA.N. Modified low density lipoprotein from diabetic patients causes cholesterol accumulation in human intimal aortic cells.Atherosclerosis19931001415410.1016/0021‑9150(93)90066‑4 8318062
    [Google Scholar]
47. LowryO. RosebroughN. FarrA.L. RandallR. Protein measurement with the Folin phenol reagent.J. Biol. Chem.1951193126527510.1016/S0021‑9258(19)52451‑6 14907713
    [Google Scholar]
48. FisherR.A. MackenzieW.A. Studies in crop variation. II. The manurial response of different potato varieties.J. Agric. Sci.192313331132010.1017/S0021859600003592
    [Google Scholar]
49. MasseyF.J.Jr. The kolmogorov-smirnov test for goodness of fit.J. Am. Stat. Assoc.195146253687810.1080/01621459.1951.10500769
    [Google Scholar]
50. StephensM.A. Kolmogorov–Smirnov Tests of Fit.John Wiley & Sons, Ltd.201610.1002/9781118445112.stat01632.pub2
    [Google Scholar]